GlassScriptPhysician profile
John A Provet
NPI 1023083078
$1,334.95
in general payments reported to CMS, 2019-2025
24 companies · $399 in 2025
The $399 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $94.31 · 2021: $243 · 2022: $216 · 2023: $107 · 2024: $24.18 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $530.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $360.47 | 2019-2023 | Myrbetriq |
| Antares Pharma, INC. | $134.83 | 2019-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $95.35 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $80.23 | 2021-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $61.16 | 2019-2022 | |
| Tolmar, INC. | $55.65 | 2025 | Jatenzo |
| Endo USA, INC. | $52.46 | 2024-2025 | Xiaflex, Aveed, Edex |
| Dentsply Ih Ab | $52.12 | 2022-2023 | Lofric |
| Pfizer INC. | $40.88 | 2019-2025 | |
| Coloplast Corp | $40.76 | 2019-2025 | |
| Urogen Pharma, INC. | $40.67 | 2022-2023 | Jelmyto |
| Dendreon Pharmaceuticals LLC | $34.92 | 2025 | Provenge |
| Ferring Pharmaceuticals INC. | $32.91 | 2025 | Adstiladrin |
| Immunitybio, INC. | $32.65 | 2025 | |
| Aytu Biopharma, INC. | $29.95 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29.52 | 2025 | |
| Endo Pharmaceuticals INC. | $24.67 | 2019 | |
| Blue Earth Diagnostics | $24.50 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $24.25 | 2022 | |
| Dentsply Ih INC. | $22.80 | 2022 | |
| Allergan, INC. | $18.04 | 2020 | |
| Neotract INC. | $16.55 | 2019 | |
| Acerus Pharmaceuticals Corporation | $16.34 | 2021 | |
| Metuchen Pharmaceuticals | $13.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Provet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.